Real-World Patterns of Systemic Therapy Attrition Highlight Gaps in TNBC Care
A study published in Breast Cancer Research and Treatment reveals that a significant percentage of patients with triple-negative breast cancer fail to initiate systemic therapy within 90 days of metastatic recurrence. This 'attrition' is associated with poorer survival outcomes and highlights a critical gap in current oncology care strategies.
Attrition of early first-line systemic anticancer therapy (SACT) for patients with triple-negative breast cancer (TNBC) “represents a meaningful gap in the care continuum and warrants improved surveillance and multidisciplinary management strategies,” according to a recent study.
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in